Industry context
Incyte Corporation [INCY]
Last Updated 24 Jun 2026 @ 16:00 (Exchange is closed)
Last: $108.46
3.89%
4.08
GaG Algo Score™
v1.0
Short
4.08
Medium
5.59 (↑)
Long
5.42 (↑)
BUY
63.27%
return 2.04%
SELL
64.00%
return -11.80%
Line
Pivot Data
Pivot Statistics
| Metric | Average | Median | Std Dev |
|---|---|---|---|
| Gain % | 17.66% | 17.66% | 0.00% |
| Loss % | N/A | N/A | N/A |
| Duration | 10.0d | 10d | 0.0d |
| Total Pivots Found | 2 |
| Gain/Loss Legs | 1 (1 Gain / 0 Loss) |
| Last Pivot | Top @ $108.53 on 2026-06-12 |
| Change since Last Pivot | $-0.07 (-0.06%) |
Next Pivot Prediction Last: $108.46
| Predicted Next Type | N/A |
| Predicted Price (Avg) | N/A |
| Predicted Price (Median) | N/A |
| Predicted Price Range (~68%) | N/A |
| Change to Avg Target | N/A (N/A) |
| Predicted Date (Avg) | 2026-06-22 |
| Predicted Date Range (~68%) | 2026-06-22 - 2026-06-22 |
| Basis | Insufficient historical loss data for prediction. and duration (Avg: 10.0 days, StdDev: 0.0 days) |
| Note | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Incyte Corporation climbs 3.89%.
Incyte Corporation (INCY) stock price showed an impressive upswing on Wednesday after the stock rose $4.06 (3.89%) from the previous session on normal volume. Showing significant relative strength, the stock rose today while the NASDAQ fell -0.43%.(The stock has risen 3 days straight. This extended rally increases the chances of a price pullback soon) Yesterday's trading volume was 1.93M shares, worth about $209.54M. This represents 260 912 shares more than the day before. Volume was close to the 10-day average of 2.28M shares.
Incyte Corporation signals
There is no conclusive signals given from RSI. The price is above both the short- and long-term averages, and the short-term average is above the long-term average, confirming an established up-trend. Strong Bullish Consensus: A powerful wave of positive momentum is evident across all timeframes. Technical indicators are decisively bullish in the short-term (18/30, net +50%), medium-term (18/30, net +50%), and long-term (18/30, net +50%), signaling a robust and sustained uptrend.
Incyte Corporation Support & Resistance Levels
The stock is approaching the closest resistance level at $108.50. approximately $0.0400 (0.04%) away. Pushing up towards resistance. Breaking above this level could signal further upside where next resistance level will be found at $109. On a fall back there will be support at $100.1 The dis das resistance s1100.1 -
Incyte Corporation Evaluation
- Short score: 4.08
- Medium score: 5.59
- Long score: 5.42
Ownership flow
GetAGraph InsiderPower
Transactions
485
Buy power
303.14M
Sell power
100.87M
Reliability
100/100
Buy / sell
3.01
Hist. corr.
-0.79
Latest signal
Buy 2026-05-06
Officer 362
Director 75
Executive 48
2026-06-08
Baker Bros. Advisors Lp Director
Buy 1 642
2026-06-08
Baker Bros. Advisors Lp Director
Buy 6 111
2026-06-08
Harrigan Edmund Director
Buy 1 642
2026-06-08
Harrigan Edmund Director
Buy 6 111
2026-06-08
Clancy Paul J Director
Buy 1 642
2026-06-08
Clancy Paul J Director
Buy 6 111
Relationship map
Correlation snapshot
<span style="background-color: lightgreen">Undervalued: <i class="arrow arrow-up"></i>0.38% <strong>$108.90</strong> paired level.</span>
Positioning pressure
Short interest pressure
Short interest
5.81%
Of outstanding shares
Short float
5.87%
Of tradable float
Days to cover
9.22
Short interest divided by average volume
Squeeze probability
12.60%
+3.28% change
Short positioning is elevated and could amplify sharp price moves.
Updated 2026-05-29Earnings quality
Earnings history
Reported quarters
10
EPS beats
4
EPS misses
6
Avg. surprise
-39.55%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q3/2025 | 2025-10-27 | - | - | - | - |
| Q2/2025 | 2025-07-29 | - | $1.370 | - | - |
| Q1/2025 | 2025-04-29 | $1.160 | $1.010 | 14.85% | 1.05B |
| Q4/2024 | 2025-02-10 | $1.430 | $1.570 | -8.92% | 1.18B |
| Q3/2024 | 2024-10-29 | $1.070 | $1.120 | -4.46% | 1.14B |
| Q2/2024 | 2024-07-30 | $-1.820 | $0.780 | -333.33% | 1.04B |
| Q1/2024 | 2024-04-30 | $0.640 | $0.840 | -23.81% | 880.89M |
| Q4/2023 | 2024-02-13 | $1.060 | $1.160 | -8.62% | 1.01B |
Analyst view
Analyst targets
Consensus
$108.55
Median
$107.00
Low
$90.00
High
$140.00
Recent target updates
News flow
Latest company news
Market coverage
247wallst.com Here Are Monday's Best Wall Street Analyst Research Calls: Accenture, Apple, Boyd Gaming, BWX Technologies, Conoco-Phillips, Estee Lauder, Hut 8, Incyte, SpaceX, and More Jun 22, 2026 zacks.com Why Incyte (INCY) is a Top Momentum Stock for the Long-Term Jun 19, 2026 businesswire.com Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Jun 19, 2026 zacks.com MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised) Jun 17, 2026Company releases
Company context
Company profile
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Currency
USD
Incyte Corporation is a biopharmaceutical firm engaged in the research development and global marketing of its own innovative therapies Its current product offerings include JAKAFI prescribed for myelofibrosis and polycythemia vera PEMAZYRE a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types and ICLUSIG a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphiachromosome positive acute lymphoblastic leukemia Beyond its marketed drugs Incytes pipeline features several promising candidates Among its clinicalstage assets are ruxolitinib targeting steroidrefractory chronic graftversushost disease GVHD and itacitinib which is undergoing Phase IIIII trials for newly diagnosed chronic GVHD Pemigatinib is also being investigated for conditions such as bladder cancer cholangiocarcinoma myeloproliferative syndrome and other tumor types Further advancing its research the company is developing Parsaclisib currently in Phase II studies for follicular lymphoma marginal zone lymphoma and mantle cell lymphoma Additionally Retifanlimab is in Phase II development for multiple indications including MSIhigh endometrial cancer Merkel cell carcinoma anal cancer and nonsmall cell lung cancer Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies including key partners like Novartis International Pharmaceutical Ltd Eli Lilly and Company and Agenus Inc among many others These collaborations extend to clinical trials notably joint efforts with MorphoSys AG and Xencor Inc to evaluate a combination therapy involving tafasitamab plamotamab and lenalidomide for patients with recurrent or resistant diffuse large Bcell lymphoma and follicular lymphoma Established in 1991 the corporations main offices are situated in Wilmington Delaware
Navigation